WIBP-CorV
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
WIBP-CorV is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show WIBP-CorV 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group).[1] The other inactivated virus COVID-19 vaccine developed by Sinopharm is BBIBP-CorV which is comparably more successful. 1 billion doses are expected to be produced per year.
Development[edit]
In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BBIBP-CorV)[2] and the Wuhan Institute of Biological Products (WIBP-CorV).[3] Both vaccines are chemically-inactivated whole virus vaccines for COVID-19.
On August 13, 2020, the Wuhan Institute of Biological Products published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy would require Phase III trials.[3]
Efficacy[edit]
In March 2021, Cayetano Heredia University running the BBIBP-CorV and WIBP-CorV trials in Peru announced they were seeking to suspend and unblind participants in the WIBP-CorV trials for lower efficacy and offer the participants BBIBP-CorV instead, which was showing efficacy.[4]
In May 2021, peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed WIBP-CorV 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received WIBP-CorV and 12,737 people received the placebo in these trials.[1]
Manufacturing[edit]
In June 2021, a new factory started production with the capacity to manufacture 1 billion doses annually.[5]
Marketing and deployment[edit]
Full authorization
Emergency authorization |
On February 25, 2021, China approved WIBP-CorV for general use.[6]
According to New York Times, the WIBP-CorV is only approved for limited use in United Arab Emirates.[7]
References[edit]
- ^ a b Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. doi:10.1001/jama.2021.8565. PMID 34037666. Retrieved 26 May 2021.
- ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (October 2020). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
- ^ a b Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. (September 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
- ^ "COMUNICADO A LA OPINIÓN PÚBLICA". Universidad Peruana Cayetano Heredia. March 9, 2021.
- ^ "Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses". CNA. Retrieved 2021-06-08.
- ^ Staff, Reuters (2021-02-25). "China approves two more domestic COVID-19 vaccines for public use". Reuters. Retrieved 2021-03-30.
- ^ Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee. "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2021-03-30.
External links[edit]
 |
Scholia has a profile for WIBP-CorV (Q106322660). |
